Notwithstanding the lack of conclusive clinical investigation of anti-IgE strategies in SLE, research on modulating pDCs to reduce IFN signatures increased by IgE complexes is especially relevant for SLE (259, 286, 287). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.